Matthew B. Coppock
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Matthew B. Coppock has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Amethist S. Finch
Sensors and Electron Devices Directorate, U.S. Army Research Laboratory, Adelphi, MD, 20783
1 shared publicationBert T. Lai
Indi Molecular, 6162 Bristol Parkway, Culver City, CA, 90230
1 shared publicationBlake Farrow
Division of Chemistry and Chemical Engineering, California Institute of Technology, 1200 East California Boulevard, Pasadena, CA, 91125
1 shared publicationBrandi Dorsey
Federal Staffing Resources, Annapolis, MD supporting U.S. Army Research Laboratory, Adelphi, MD, 20783
1 shared publicationCandice R. Warner
Excet, Springfield, VA 22151 supporting USA Edgewood Chemical Biological Center, Aberdeen Proving Ground, MD, 21010
1 shared publicationDeborah A. Sarkes
Sensors and Electron Devices Directorate, U.S. Army Research Laboratory, Adelphi, MD, 20783
1 shared publication
Latest Publications
- Open Access
A universal method for the functionalization of dyed magnetic microspheres with peptides
- Open Access
- 25 March 2017
- Published by Wiley in Peptide Science
- Vol. 108 (2)
Protein catalyzed capture agents with tailored performance forin vitroandin vivoapplications
We report on peptide‐based ligands matured through the protein catalyzed capture (PCC) agent method to tailor molecular binders forin vitrosensing/diagnostics andin vivopharmacokinetics parameters. A vascular endothelial growth factor (VEGF) binding peptide and a peptide against the protective antigen (PA) protein ofBacillus anthracisdiscovered through phage and bacterial display panning technologies, respectively, were modified with click handles and subjected to iterativein situclick chemistry screens using synthetic peptide libraries. Each azide‐alkyne cycloaddition iteration, promoted by the respective target proteins, yielded improvements in metrics for the application of interest. The anti‐VEGF PCC was explored as a stablein vivoimaging probe. It exhibited excellent stability against proteases and a mean eliminationin vivohalf‐life (T1/2) of 36 min. Intraperitoneal injection of the reagent results in slow clearance from the peritoneal cavity and kidney retention at extended times, while intravenous injection translates to rapid renal clearance. The ligand competed with the commercial antibody for binding to VEGFin vivo. The anti‐PA ligand was developed for detection assays that perform in demanding physical environments. The matured anti‐PA PCC exhibited no solution aggregation, no fragmentation when heated to 100°C, and > 81% binding activity for PA after heating at 90°C for 1 h. We discuss the potential of the PCC agent screening process for the discovery and enrichment of next generation antibody alternatives.
- 25 March 2017
- Published by Wiley in Peptide Science
- Vol. 108 (2)
Open AccessProtein catalyzed capture agents with tailored performance forin vitroandin vivoapplications
We report on peptide‐based ligands matured through the protein catalyzed capture (PCC) agent method to tailor molecular binders forin vitrosensing/diagnostics andin vivopharmacokinetics parameters. A vascular endothelial growth factor (VEGF) binding peptide and a peptide against the protective antigen (PA) protein ofBacillus anthracisdiscovered through phage and bacterial display panning technologies, respectively, were modified with click handles and subjected to iterativein situclick chemistry screens using synthetic peptide libraries. Each azide‐alkyne cycloaddition iteration, promoted by the respective target proteins, yielded improvements in metrics for the application of interest. The anti‐VEGF PCC was explored as a stablein vivoimaging probe. It exhibited excellent stability against proteases and a mean eliminationin vivohalf‐life (T1/2) of 36 min. Intraperitoneal injection of the reagent results in slow clearance from the peritoneal cavity and kidney retention at extended times, while intravenous injection translates to rapid renal clearance. The ligand competed with the commercial antibody for binding to VEGFin vivo. The anti‐PA ligand was developed for detection assays that perform in demanding physical environments. The matured anti‐PA PCC exhibited no solution aggregation, no fragmentation when heated to 100°C, and > 81% binding activity for PA after heating at 90°C for 1 h. We discuss the potential of the PCC agent screening process for the discovery and enrichment of next generation antibody alternatives.